The U.S. Food and Drug Administration has cleared ArteraAI Breast for use in patients with early-stage, hormone receptor (HR) ...

Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or death by 30% in ER-positive, HER2-negative early breast cancer. The ...

Giredestrant improved invasive disease-free survival in estrogen receptor-positive, HER2-negative early breast cancer, marking a significant advancement for SERDs in the adjuvant setting. The lidERA ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer and residual disease after neoadjuvant therapy are at high risk for recurrence. In a phase 3, open-label, ...

Findings showed giredestrant led to a statistically significant and clinically meaningful improvement in iDFS vs physician’s choice of endocrine therapy at the pre-planned interim analysis. Topline ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society ...

Roche’s Genentech unit is emphasizing next-generation breast cancer therapies, targeted oncology combinations and ...

How Does Kisqali Work for Breast Cancer? Kisqali is a specific kind of medicine called a kinase inhibitor. Kinases are enzymes that are responsible for sending and receiving signals in the body. These ...

Hearing the words “triple-negative breast cancer” (TNBC) can be overwhelming. It’s a diagnosis that sounds heavy — not just because breast cancer itself is frightening, but because this particular ...